ABL Bio Inc. (298380.KQ)
KRW 67200.0
(3.07%)
KRW 67200.0
(3.07%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 43.93 Billion KRW | 5.02% |
| 2022 | 41.83 Billion KRW | 7184.01% |
| 2021 | 574.35 Million KRW | -61.6% |
| 2020 | 1.49 Billion KRW | -20.47% |
| 2019 | 1.88 Billion KRW | 0.0% |
| 2018 | - KRW | -100.0% |
| 2017 | 7.62 Billion KRW | 227.76% |
| 2016 | 2.32 Billion KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 43.6 Billion KRW | -0.77% |
| 2024 Q2 | 43.47 Billion KRW | -0.3% |
| 2023 Q1 | 41.53 Billion KRW | -0.71% |
| 2023 Q4 | 43.93 Billion KRW | 6.52% |
| 2023 Q3 | 41.24 Billion KRW | 0.02% |
| 2023 Q2 | 41.24 Billion KRW | -0.71% |
| 2023 FY | 43.93 Billion KRW | 5.02% |
| 2022 Q1 | 407.9 Million KRW | -28.98% |
| 2022 Q4 | 41.83 Billion KRW | 1913.07% |
| 2022 Q3 | 2.07 Billion KRW | 2.87% |
| 2022 Q2 | 2.02 Billion KRW | 395.27% |
| 2022 FY | 41.83 Billion KRW | 7184.01% |
| 2021 FY | 574.35 Million KRW | -61.6% |
| 2021 Q2 | 1.04 Billion KRW | -17.7% |
| 2021 Q4 | 574.35 Million KRW | -28.33% |
| 2021 Q3 | 801.42 Million KRW | -23.15% |
| 2021 Q1 | 1.26 Billion KRW | 0.0% |
| 2020 FY | 1.49 Billion KRW | -20.47% |
| 2019 FY | 1.88 Billion KRW | 0.0% |
| 2018 FY | - KRW | -100.0% |
| 2017 FY | 7.62 Billion KRW | 227.76% |
| 2016 FY | 2.32 Billion KRW | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Sam Chun Dang Pharm. Co., Ltd | 53.62 Billion KRW | 18.064% |
| Hyundai Bioscience Co., Ltd. | 5.54 Billion KRW | -692.17% |
| ST Pharm Co.,Ltd. | 192.08 Billion KRW | 77.125% |
| Cellid, Co., Ltd. | 11.99 Billion KRW | -266.308% |